Foscenvivint (PRI 724 or OP 724)[1] is a CREB-binding protein/β-catenin inhibitor that is developed for the treatment of liver diseases[2] such as primary biliary cholangitis,[3] hepatocellular carcinoma,[4][5] and hepatitis C and B virus-induced liver cirrhosis.

[6][7]